ARCHIVES

GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile

This article is from The Cancer Letter archive.

Vol. 36 No. 8 | August 30, 2013

Download PDF Visit The Full Archive

Related Articles

ODAC Votes Against Adria’s Chemoprotector, Okays Leustatin

July 3, 1992

Bill Planned To Okay Medicare/Medicaid Payment For 100% Of Outpatient Anticancer Drug Costs

February 16, 1979

In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs

January 17, 1992

Exit Joseph Nevins: Duke’s Genomics Luminary Quietly Leaves

October 18, 2013

Clinical Trials Approved By NCI CTEP Last Month

February 25, 2011

ACS Asks Higher NCI Authorization

March 24, 1978